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Identity 
Other names: MKP-3, MKP3, PYST1, rVH6 




The human DUSP6 gene is located on chromosome 
12q21.33 and consists of 3 exons. The full-length 
coding sequence of DUSP6 contains 1146 nucleotides. 
The functional phosphatase domain of DUSP6 is 
encoded by half of exon 2 and almost the entire 
sequence of exon 3. 
Transcription 
DUSP6 gene transcription can start from either the first 
ATG or alternatively the second ATG (Met14), and 
therefore two protein products are generated which 
usually demonstrate a double-band appearance in 
regular immunoblotting assays (Dowd et al., 1998; 
Zhang et al., 2010). 
Protein 
Description 
The full-length DUSP6 protein contains 381 amino 
acids and has a molecular weight of 44 kDa. DUSPs 
are characterized by a common structure comprising a 
C-terminal phosphatase domain that are defined by the 
active-site signature motif HCXXXXXR. The structure 
of DUSP proteins confers phosphatase activity for both 
phosphoserine/threonine and phosphotyrosine residues. 
An enzyme-dead DUSP6 expression construct can be 
generated via a 293 Cysteine to Serine/Glycine 
(C293S/G) point mutation (Wishart et al., 1995; Zhang 
et al., 2010; Zhou et al., 2006). 
Expression 
DUSP6 is expressed usually at low level in resting, 
nonstimulated cells in a variety of tissues and is 
induced as an early response gene after activation of 
the ERK-MAPK signaling pathway. 
 
 
The diagram depicts the structure of the DUSP6 gene (bottom) roughly aligned with its corresponding functional protein domains (middle 
and top). DUSP6 comprises a C-terminal catalytic domain and an N-terminal non-catalytic domain (middle). The 3 exons of DUSP6 
(rectangles) are connected with lines representing introns. 
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The diagram depicts the structural features of DUSP6. The highly conserved C-terminal domain of DUSP6 contains the canonical 
tyrosine/threonine-specific phosphatase signature sequence HCXXXXXR at the active site, where the cysteine acts as the essential 
enzymatic nucleophile and arginine interacts directly with the phosphate group on phosphotyrosine or phosphothreonine (Farooq et al., 
2001). The amino-terminal domain of DUSP6 contains a specific arginine-rich kinase interaction motif (KIM) (Tárrega et al., 2005) and a 
leucine-rich nuclear export signal (NES) necessary and sufficient for nuclear export of the phosphatase (Karlsson et al., 2004). 
 
Localisation 
DUSP6 is a cytoplasmic dual specificity protein 
phosphatase. 
Function 
Mitogen-activated protein kinases (MAPK) constitute a 
highly conserved family of kinases that relay 
information from extracellular signals to downstream 
effectors that control diverse cellular processes such as 
proliferation, differentiation, migration, survival and 
apoptosis (Wada and Penninger, 2004). A balance 
between the activities of upstream activators and 
various negative regulatory mechanisms of MAPK 
signaling, which terminate its activation, determines its 
biological outcomes. DUSP6 is a prototypical member 
of a subfamily of cytoplasmic MKPs, which includes 
DUSP7 and DUSP9 as well. These enzymes all display 
a high degree of substrate selectivity for ERK1 and 
ERK2 (Keyse, 2008). DUSP6 has been shown to act as 
a central feedback regulator attenuating ERK levels in 
developmental programs (Echevarria et al., 2005; Li et 
al., 2007). The cytoplasmic localization of DUSP6 is 
mediated by a chromosome region maintenance-1-
dependent nuclear export pathway. DUSP6 appears to 
play a role in determining the subcellular localization 
of ERK by serving as a cytoplasmic anchor for ERK, 
thereby mediating a spatio-temporal mechanism of 
ERK signaling regulation. Cytoplasmic retention of 
ERK requires both a functional kinase interaction motif 
and nuclear export site. Defects of these feedback 
regulation steps are thought to contribute to ERK-
MAPK related oncogenesis. An in vivo study has 
identified DUSP6 as a negative feedback regulator of 
fibroblast growth factor-stimulated ERK signaling 
during murine development (Li et al., 2007). Several in 
vitro studies have demonstrated that DUSP6 acts as a 
negative regulator of fibroblast growth factor receptor 
signaling and endothelial cell platelet-derived growth 
factor receptor signaling via termination of ERK 
activation (Ekerot et al., 2008; Jurek et al., 2009). 
Homology 
DUSP6 belongs to a subfamily of ten more closely 
related dual-specificity MAPK phosphatases (MKPs) 
within the larger cysteine-dependent dual specificity 
phosphatase (DUSP) family (Keyse, 2008). While 
DUSP1 (MKP-1), DUSP4 (MKP-2), and DUSP9 
(MKP4) dephosphorylate both ERKs, p38 and JNK, the 
phosphatases DUSP5 (Hvh-3), DUSP6 (MKP-3), and 
DUSP7 (MKP-X) exclusively target ERK1/2 MAPKs 
(Keyse, 2008). The N-terminal domain of all DUSPs 
has two regions of homology with the Cdc25 cell cycle 
regulatory phosphatase. The more conserved catalytic 
domain within DUSPs contains an active site sequence 
related to the prototypic VH-1 phosphatase encoded by 
the vaccinia virus. Specificity of MKPs toward MAPKs 
relies on the KIM domain. Although each MKP targets 
different subsets of MAPKs, there is an overlap 
between their specificities (Bermudez et al., 2010). 
Mutations 
Note 
Although DUSP6 has been implicated as a candidate 
tumor suppressor in several cancer setting, no 




DUSP6 null mice demonstrate enhanced ERK1/2 
phosphorylation leading to increased myocyte 
proliferation and cardiac hypercellularity (Maillet et al., 
2008). DUSP6 has been identified as a potential novel 
tumor suppressor gene in pancreatic cancer since loss 
of DUSP6 expression might synergize with activating-
mutated k-Ras resulting in increased activation of 
ERK1/2 MAP kinase and thus contribute to the 
development of the malignant and invasive phenotype 
in pancreatic cancer (Furukawa et al., 2003). Loss of  
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DUSP6 expression caused by oxidative stress-mediated 
degradation was also noted in ovarian cancer and 
correlated with high ERK1/2 activity (Chan et al., 
2008). DUSP6 has also been identified as one of only 
three genes which are uniquely expressed in myeloma 
cells harboring a constitutively active mutant N-ras 
gene and is also overexpressed in human melanoma 
cell lines with potent activating mutations in B-raf and 
in breast epithelial cells stably expressing H-Ras 
(Bloethner et al., 2005; Croonquist et al., 2003; 
Warmka et al., 2004), suggesting that the over-
expression of DUSP6 seen in response to activating-
mutated Ras or Raf might represent a compensatory 
increase in the negative feedback control of the 
ERK1/2 MAPK pathway, which lies downstream of 
these activated oncogenes. In support of this, the 
tetracycline-induced expression of a functional fusion 
protein between DUSP6 and green fluorescent protein 
in H-ras transformed fibroblasts following injection 
into nude mice resulted in a large delay in tumor 
emergence and growth as compared to the untreated 
control group (Marchetti et al., 2004 ). DUSP6 has 
been reported to be one of the most highly regulated 
genes in chronic myeloid leukemia cells upon imatinib 
treatment (Hakansson et al., 2008) and similarly 
DUSP6 is overexpressed upon inducible expression of 
the EGFRvIII oncogene in glioblastoma cells 
(Ramnarain et al., 2006). DUSP6 has also been 
demonstrated to be positively correlated with the 
activity of the oncogenic ERK pathway in non-small 
cell lung cancer tissue and is an ETS-regulated negative 
feedback mediator of ERK signaling in lung cancer 
cells (Zhang et al., 2010). 
Prognosis 
Elevated DUSP6 RNA expression was reported to be a 
major negative predictor of survival in patients with 
resected non-small cell lung cancer as part of a five-
gene signature model (Chen et al., 2007). 
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